Companies › Annexin Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ANXV Human recombinant Annexin A5 protein; proposed mechanism involves binding to phosphatidyls | ANXA5 | Phase 2 | Non-Proliferative Diabetic Retinopathy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07259928 | ANXV | Phase 2 | Non-Proliferative Diabetic Retinopathy | Ophthalmology | Jul 2026 |
–
Beacon Therapeutics Qlaris Bio Aperta Biosciences Jiangsu Jingze Biopharmaceutical ONL Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.